Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialAdrian F. Hernandez, Lauren B. Cooper, David C. M. Kong et al.|The Lancet|2018Cited by 1.8k
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery DiseaseWilliam R. Hiatt, Manesh R. Patel, F. Gerry R. Fowkes et al.|New England Journal of Medicine|2016Cited by 628
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesHeather L. Gornik, Luke R. Wilkins, Herbert D. Aronow et al.|Circulation|2024Cited by 549
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 studyJonathan P. Piccini, Veronika Eder, Valeria Caso et al.|The Lancet|2022Cited by 310
2020 ACC/AHA guideline for the management of patients with valvular heart diseaseCatherine M Otto, Y. Joseph Woo, Rick A. Nishimura et al.|Journal of Thoracic and Cardiovascular Surgery|2021Cited by 251